Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1092 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-12-15

Study Completion Date

2017-06-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is conducted in Asia. The aim of this trial is to evaluate safety and effectiveness of Victoza® in patients with type 2 diabetes mellitus (T2DM) in combination with antidiabetes agents other than sulfonylurea under post-marketing normal clinical practice conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

NCT01821846

Diabetes Diabetes Mellitus, Type 2

COMPLETED

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00393718

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE3

Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00395746

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE3

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

NCT02730377

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE4

Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes

NCT01226966

Diabetes Diabetes Mellitus, Type 2

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Liraglutide

liraglutide

Intervention Type DRUG

Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions.

No treatment given.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

liraglutide

Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions.

No treatment given.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent obtained before any study-related activities (Study-related activities are any procedure related to recording of data according to the protocol)
* Patients with T2DM (type 2 diabetes mellitus) who the physician has decided to start treatment with Victoza® in combination with insulin or OAD (oral anti-diabetes drug) other than SU (sulfonylurea)
* Male or female, no age limitation

Exclusion Criteria

* Previous participation in this study or NN2211-3772 Participation is defined as informed consent obtained for this study or enrolment for NN2211-3772
* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
* Patients who are on Victoza® or have previously been on Victoza® within 3 month before the enrolment

Eligible Sex

ALL

Accepts Healthy Volunteers

No